Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana

被引:286
作者
Weiser, S
Wolfe, W
Bangsberg, D
Thior, I
Gilbert, P
Makhema, J
Kebaabetswe, P
Dickenson, D
Mompati, K
Essex, M
Marlink, R
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Med, Dept Med, San Francisco, CA 94110 USA
[2] Div Infect Dis, Epidemiol & Prevent Intervent Ctr, San Francisco, CA USA
[3] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana
[4] Harvard Univ, Sch Publ Hlth, Harvard AIDS Inst, Cambridge, MA 02138 USA
关键词
adherence; compliance; highly active antiretroviral; therapy; Africa; Botswana; treatment barriers;
D O I
10.1097/00126334-200311010-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Botswana has the highest rate of HIV infection in the world, estimated at 36% among the population aged 15-49 years. To improve antiretroviral (ARV) treatment delivery, we conducted a cross-sectional study of the social, cultural, and structural determinants of treatment adherence. Methods: We used both qualitative and quantitative research methodologies, including questionnaires and interviews with patients receiving ARV treatment and their health care providers to elicit principal barriers to adherence. Patient report and provider estimate of adherence (greater than or equal to95% doses) were the primary outcomes. Results: One hundred nine patients and 60 health care providers were interviewed between January and July 2000; 54% of patients were adherent by self-report, while 56% were adherent by provider assessment. Observed agreement between patients and providers was 68%. Principal barriers to adherence included financial constraints (44%), stigma (15%), travel/migration (10%), and side effects (9%). On the basis of logistic regression, if cost were removed as a barrier, adherence is predicted to increase from 54% to 74%. Conclusions: ARV adherence rates in this study were comparable with those seen in developed countries. As elsewhere, health care providers in Botswana were often unable to identify which patients adhere to their ARV regimens. The cost of ARV therapy was the most significant barrier to adherence.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 30 条
[1]  
Ammassari A, 2001, J ACQ IMMUN DEF SYND, V28, P445, DOI 10.1097/00042560-200112150-00006
[2]   Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring [J].
Arnsten, JH ;
Demas, PA ;
Farzadegan, H ;
Grant, RW ;
Gourevitch, MN ;
Chang, CJ ;
Buono, D ;
Eckholdt, H ;
Howard, AA ;
Schoenbaum, EE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1417-1423
[3]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[4]   Non-adherence to highly active antiretroviral therapy predicts progression to AIDS [J].
Bangsberg, DR ;
Perry, S ;
Charlebois, ED ;
Clark, RA ;
Roberston, M ;
Zolopa, AR ;
Moss, A .
AIDS, 2001, 15 (09) :1181-1183
[5]  
Bangsberg DR, 2001, J ACQ IMMUN DEF SYND, V26, P435, DOI 10.1097/00126334-200104150-00005
[6]  
BYAKIKATUSIIME J, 2003, 10 C RETR OPP INF BO
[7]   Factors affecting adherence to antiretroviral therapy [J].
Chesney, MA .
CLINICAL INFECTIOUS DISEASES, 2000, 30 :S171-S176
[8]  
Chesney MA, 1999, AIDS, V13, pS271
[9]   Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments [J].
Chesney, MA ;
Ickovics, JR ;
Chambers, DB ;
Gifford, AL ;
Neidig, J ;
Zwickl, B ;
Wu, AW .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03) :255-266
[10]   Adherence to HIV combination therapy [J].
Chesney, MA ;
Morin, M ;
Sherr, L .
SOCIAL SCIENCE & MEDICINE, 2000, 50 (11) :1599-1605